Abstract:Objective To study the relationship between the chemokine CX3CL1/ CX3CR1 and platinum drug resistance, as well as prognosis in ovarian cancer patients. To dynamically detect the resistance nude mice model of CX3CL1 and its receptor CX3CR1 in the course of platinum resistance. To analyze the expression of CX3CL1, CX3CR1 and the correlation of Fas signaling pathway. Methods The cancer gene atlas(TCGA) database of patients with ovarian cancer genome-wide expression was employed to analyze the relation-ship of CX3CL1/ CX3CR1 in platinum sensitivity or resistant patients with clinical features. Ovarian cancer SKOV3 sensitive cells(SK-OV3-GFP) with green fluorescent marker and cisplatin resistant cells(SKOV3-GFP / DDPⅢ) were subcutaneously injected in nude mice. After xenograft was constracted, cisplatin was intraperitoneally injected. Real time fluorescence quantitative-PCR(qRT-PCR) was used to detect the expression of CX3CL1, CX3CR1 and genes on Fas signal pathway after 0, 2, 5, 8 times of cisplatin injection. Results CX3CL1 expression was negatively correlated with FIGO and platinum resistance(r=-0. 112,P= 0. 030;r=-0. 106,P= 0. 044), CX3CR1 expression was negatively correlated with progression-free survival time(r = -0. 130,P = 0. 029) and positively correlated with 1-year re-lapse rate(r= 0. 119,P = 0. 045). The average expression of CX3CL1 in platinum sensitive group was 3. 96±0. 039, higher than 3. 64± 0. 55 of platinum resistant group(P= 0. 000). After the intervention of cisplatin, xenograft grew gradually. The weight of xenograft in SK-OV3-GFP / DDPⅢ group was higher than SKOV3-GFP group, and xenograft in the both two groups shrank at the fifth time of infection. After cisplatin stimulation, the expression of CX3CL1/ CX3CR1 in SKOV3-GFP group increased significantly(P= 0. 001, P= 0. 002), but it remained low in SKOV3-GFP / DDPⅢ group. The expression of Fas and FADD of Fas signal pathway in SKOV3 GFP / DDPⅢ group was also significantly lower than them in SKOV3-GFP group(P<0. 001). However, PARP1 gene significantly rose in SKOV3GFP / DDPⅢgroup than that in SKOV3-GFP group(P<0. 001). The expression of CX3CL1 and CX3CR1 was positively correlated with Fas and FADD, while it was negatively correlated with PARP1 of Fas signaling pathways. Conclusion The down-regulation of CX3CL1 and CX3CR1 is associated with platinum resistance. They may play a role in maintain the sensitivity of tumor cells to platinum. The low expression of CX3CL1 and CX3CR1 may suppress Fas signal pathway through some mechanism, resulting in transduction disorder, inhibiting cell apop-tosis and inducing platinum resistance of ovarian cancer. The lower expression of drug-resistant cells may be a mechanism inhibiting Fas signaling pathways, which make its conduction misbalance, finally inhibiting cell apoptosis, inducing the resistance of ovarian cancer. It may be a platinum promote ovarian cancer therapy targeting molecules.

Aurora-A/SOX8/FOXK1 signaling axis promotes chemoresistance via suppression of cell senescence and induction of glucose metabolism in ovarian cancer organoids and cells

Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance

ALKBH5-HOXA10 loop-mediated JAK2 m6A demethylation and cisplatin resistance in epithelial ovarian cancer

The feedback loop of AURKA/DDX5/TMEM147-AS1/let-7 drives lipophagy to induce cisplatin resistance in epithelial ovarian cancer

The Fibrillin‐1/VEGFR2/STAT2 signaling axis promotes chemoresistance via modulating glycolysis and angiogenesis in ovarian cancer organoids and cells

Targeting IGF1R signaling enhances the sensitivity of cisplatin by inhibiting proline and arginine metabolism in oesophageal squamous cell carcinoma under hypoxia

Sequential treatment with aurora B inhibitors enhances cisplatin-mediated apoptosis via c-Myc

DUOXA1-mediated ROS Production Promotes Cisplatin Resistance by Activating ATR-Chk1 Pathway in Ovarian Cancer.

ABT737 Reverses Cisplatin Resistance by Targeting Glucose Metabolism of Human Ovarian Cancer Cells

Aurora Kinase A Inhibition Potentiates Platinum and Radiation Cytotoxicity in Non-Small-Cell Lung Cancer Cells and Induces Expression of Alternative Immune Checkpoints

Chemokine CX3CL1/CX3CR1 biological axis promote ovarian cancer cell apotosis induced by platinum drug

Modeling of senescence-related chemoresistance in ovarian cancer using data analysis and patient-derived organoids

Abstract B003: A multi-omic analysis to identify epigenetic drivers of platinum-resistance in high-grade serous ovarian carcinoma models

Abstract A033: The transcriptional landscape of cisplatin resistance and its relationship with epithelial mesenchymal transition in ovarian cancer

Aurora-A contributes to cisplatin resistance and lymphatic metastasis in non-small cell lung cancer and predicts poor prognosis

CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer

Anlotinib induces apoptosis and second growth/mitosis phase block in cisplatin-resistant ovarian cancer cells via the aurora kinase A/p53 pathway

Lnc-RP11-536 K7.3/SOX2/HIF-1α signaling axis regulates oxaliplatin resistance in patient-derived colorectal cancer organoids

Cisplatin-induced PANDAR-Chemo-EVs contribute to a more aggressive and chemoresistant ovarian cancer phenotype through the SRSF9-SIRT4/SIRT6 axis

ALKBH5-HOXA10 loop-mediated JAK2 m6A demethylation and platinum resistance in epithelial ovarian cancer

High Expression of Aurora-B is Correlated with Poor Prognosis and Drug Resistance in Non-Small Cell Lung Cancer